17 October 2017
News and Views
Links and Services
This week's issue of the New England Journal of Medicine investigates ustekinumab as an intravenous induction therapy in 2 populations with moderately to severely active Crohn’s disease.
Dr Brian Feagan and colleagues evaluated ustekinumab, a mono
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors